Drug intelligence / Profile preview

influenza a (h1n1) 2009 vaccine

Development stage
Approved
Lead developer
Sanofi Pasteur
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular, Intranasal
01

Overview

Influenza A (H1N1) 2009 vaccine is a monovalent vaccine developed in response to the 2009 H1N1 influenza pandemic. It is designed for active immunization against disease caused by the pandemic influenza A (H1N1) 2009 virus. The vaccine is produced using the A/California/7/2009 (H1N1)pdm strain and is available in both inactivated and live, attenuated formulations, with specific formulations prepared as purified surface antigen subunits or as live attenuated virus. The inactivated vaccines are administered intramuscularly and contain non-infectious particles, while the live attenuated version is administered intranasally. The vaccine operates as an immunotherapy, stimulating host immune responses to develop protective antibodies primarily against hemagglutinin and neuraminidase surface antigens of the influenza virus[1][3][4].

Other names
h1n1 vaccineh-1n1 vaccineh 1n1 vaccinepandemic h1n1 2009 vaccineswine flu vaccine (2009 pandemic)
02

Targets

HA (Hemagglutinin)Neuraminidase

Beyond the preview

Go deeper on influenza a (h1n1) 2009 vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on influenza a (h1n1) 2009 vaccine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call